Cladribine tablets produce selective and discontinuous reduction of B and T lymphocytes and natural killer cells in patients with early and relapsing multiple sclerosis (ORACLE-MS, CLARITY and CLARITY Extension)

被引：0
|
作者：
Stuve, O. [1 ]
Soelberg-Sorensen, P. [2 ]
Giovannoni, G. [3 ]
Leist, T. [4 ]
Hyvert, Y. [5 ]
Damian, D. [5 ]
Boschert, U. [5 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[2] Univ Copenhagen, Rigshosp, Dept Neurol, Copenhagen, Denmark
[3] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
[4] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA
[5] EMD Serono Inc, Billerica, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P690
引用
收藏
页码：335 / 336
页数：2
相关论文
共 37 条
  • [21] Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
    Giovannoni, Gavin
    Sorensen, Per Soelberg
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Comi, Giancarlo
    Dangond, Fernando
    Adeniji, Abidemi K.
    Vermersch, Patrick
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (12) : 1594 - 1604
  • [22] Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study
    Comi, Giancarlo
    Cook, Stuart
    Rammohan, Kottil
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Adeniji, Abidemi K.
    Dangond, Fernando
    Giovannoni, Gavin
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11 : 1 - 11
  • [23] Year-by-year lymphopenia rates in patients with relapsing multiple sclerosis (RMS) treated with cladribine tablets 3.5mg/kg in CLARITY and re-treated in CLARITY Extension
    Cook, Stuart
    Comi, Giancarlo
    Giovannoni, Gavin
    Rieckmann, Peter
    Soelberg-Sorensen, Per
    Vermersch, Patrick
    Dangond, Fernando
    Hicking, Christine
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (13) : NP11 - NP11
  • [24] Year-by-year lymphopenia rates in patients with relapsing multiple sclerosis (RMS) treated with cladribine tablets 3.5mg/kg in CLARITY and re-treated in CLARITY Extension
    Cook, S.
    Comi, G.
    Giovannoni, G.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Dangond, F.
    Hicking, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 195 - 196
  • [25] CLARITY extension: sustained efficacy in relapsing remitting multiple sclerosis following switch from cladribine tablets to placebo in patients with high disease activity at baseline
    Vermersch, P.
    Giovannoni, G.
    Soelberg-Sorensen, P.
    Keller, B.
    Jack, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 867 - 867
  • [26] Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis Analysis of Economic Data from the CLARITY Study
    Ali, Shehzad
    Paracha, Noman
    Cook, Stuart
    Giovannoni, Gavin
    Comi, Giancarlo
    Rammohan, Kottil
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Greenberg, Steven
    Scott, David A.
    Joyeux, Alexandre
    CLINICAL DRUG INVESTIGATION, 2012, 32 (01) : 15 - 27
  • [27] Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies
    Gavin Giovannoni
    Giancarlo Comi
    Kottil Rammohan
    Peter Rieckmann
    Fernando Dangond
    Birgit Keller
    Dominic Jack
    Patrick Vermersch
    Advances in Therapy, 2021, 38 : 4975 - 4985
  • [28] Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies
    Giovannoni, Gavin
    Comi, Giancarlo
    Rammohan, Kottil
    Rieckmann, Peter
    Dangond, Fernando
    Keller, Birgit
    Jack, Dominic
    Vermersch, Patrick
    ADVANCES IN THERAPY, 2021, 38 (09) : 4975 - 4985
  • [29] Clinical Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results fro the 120-Week Phase IIIb Extension Trial to the CLARITY Study
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart
    Rieckmann, Peter
    Rammohan, Kottil
    Soelberg-Soerensenn, Per
    Vermersch, Patrick
    Martin, Emily
    Dangond, Fernando
    NEUROLOGY, 2016, 86
  • [30] Clinical efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS): final results from the 120-week Phase IIIb extension trial to the CLARITY study
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rieckmann, P.
    Rammohan, K.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Martin, E.
    Dangond, F.
    SWISS MEDICAL WEEKLY, 2016, 146 : 79S - 79S
1234